Itchy, inflamed, flaring eczema? Get expert atopic dermatitis management including topical steroids, tacrolimus, emollient therapy, and trigger identification — without leaving home.

Board-Certified HIPAA-Compliant Same-Day Available DE · MD · WA

Book a Same-Day Visit →

Understanding Atopic Dermatitis — Pathophysiology & Triggers

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin condition affecting approximately 31 million Americans. It is the most common form of eczema and is characterized by skin barrier dysfunction, immune dysregulation (Th2-skewed immune response), and intense pruritus. The loss-of-function mutations in the filaggrin gene (FLG) — a structural protein essential to the epidermal barrier — are among the most well-established genetic risk factors, leading to increased transepidermal water loss, dry skin (xerosis), and heightened skin susceptibility to environmental irritants and allergens. AD frequently presents alongside asthma and allergic rhinitis — the so-called "atopic triad."

The itch-scratch cycle is a central feature of atopic dermatitis and one of the most burdensome aspects of the disease. Pruritus — often worse at night — drives scratching, which further damages the skin barrier, introduces pathogens, and perpetuates inflammation. Breaking this cycle is a primary therapeutic goal. Understanding and identifying individual triggers is equally important: common triggers include fragrances and preservatives in soaps and lotions, wool and synthetic fabrics, hot showers, sweat, certain foods (in some patients, particularly children), stress, environmental allergens such as dust mites and pet dander, and extremes of temperature.

Atopic dermatitis distribution varies by age and chronicity. In adults, AD typically affects the flexural areas — antecubital and popliteal fossae, wrists, neck, and periorbital regions — and may present with lichenification (skin thickening from chronic scratching) and excoriations. your board-certified provider, assesses disease extent and severity during your telehealth visit using validated tools such as the Eczema Area and Severity Index (EASI) framework, adapted for the video visit context via photo submission and structured symptom review.

Eczema Treatments Available Online

Topical Corticosteroid Potency — Getting It Right

One of the most common clinical errors in eczema management — and a major driver of treatment failure — is under-treating with inadequate steroid potency, paradoxically leading to prolonged disease exposure and greater total steroid burden. AAD guidelines and the National Eczema Association both emphasize using the correct potency for the correct body region for the correct duration. Low-potency steroids (Class VI–VII, such as hydrocortisone 1%) are appropriate for sensitive areas including the face, eyelids, axillae, and groin. Mid-potency agents (Class III–V, such as triamcinolone 0.1%) are the workhorse for trunk and extremity disease. High-potency steroids (Class I–II, such as clobetasol 0.05%) are reserved for palms, soles, and short-term severe flares on non-sensitive body sites.

Topical calcineurin inhibitors — tacrolimus (Protopic) and pimecrolimus (Elidel) — are non-steroidal immunomodulators that are particularly valuable for areas where long-term steroid use carries the greatest risk of side effects: the face, periorbital region, and skin folds. They carry a black box warning regarding theoretical malignancy risk (not established in clinical evidence) but are recommended by the AAD as steroid-sparing options for maintenance therapy and sensitive sites. Tacrolimus 0.1% is the more potent formulation appropriate for adults, while 0.03% is used in children.

For patients with moderate-to-severe atopic dermatitis refractory to topical therapies, dupilumab (Dupixent) — an IL-4/IL-13 receptor antagonist biologic — represents a major treatment advance. Dupilumab is highly effective and has a favorable safety profile, but it requires injectable administration, specialty pharmacy coordination, and dermatology co-management. Innocre will identify patients who may be candidates for dupilumab and facilitate a dermatology referral with relevant clinical documentation to expedite the evaluation process.